SUBCUT-HF II Patient Satisfaction Survey

• Research type

  Research Study

• Full title

  The experience of patients or the carers of patients enrolled in the SUBCUT-HF II clinical trial who were randomised to Early Supported Discharge treatment strategy with a novel subcutaneous furosemide at home.

• IRAS ID

  357909

• Contact name

  Joanna Osmanska

• Contact email

  Joanna.Osmanska@glasgow.ac.uk

• Duration of Study in the UK

  0 years, 6 months, 1 days

• Research summary

  Furosemide is a diuretic that is very effective for the treatment of worsening symptoms of heart failure. Current preparations of furosemide can be administered into a vein (intravenously) or by mouth. A new preparation of furosemide which can be given under the skin (subcutaneously) has been recently developed.

  The SUBCUT-HF II trial enrolled patients who were admitted to hospital with worsening heart failure. As part of the trial patients were allocated to two treatment arms: Early Supported Discharge using new preparation of furosemide given through a pump subcutaneously at home or the Usual Care where furosemide is given into a vein in hospital.
  SUBCUT-HF II Patient Satisfaction Survey is a short 20-question survey for the patients who were treated with a subcutaneous furosemide pump at home and were recruited at either the Glasgow Royal Infirmary or Queen Elizabeth University Hospital in Glasgow. If the patient prefers, then someone who looked after them during the trial (carer) can complete the survey instead.

  This survey has a mix of closed and open-ended questions. This survey will be delivered to participants through either an over-the-phone interview, a mail questionnaire, or an in-person interview.
  The aim of this study is to assess what the patients (or carers) liked and disliked about the new treatment with subcutaneous furosemide at home. We will also look at whether the patients required any assistance while being treated at home, and what improvements the patients/carers would like to be made for future patients treated with the subcutaneous furosemide administered with new device.
  

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  26/YH/0040

• Date of REC Opinion

  30 Mar 2026

• REC opinion

  Further Information Favourable Opinion